EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Prognostic Value of Left Ventricular Endomyocardial Biopsy in Dilated Cardiomyopathy

Elham Kayvanpour, Farbod Sedaghat-Hamedani, Daniel Tian Li, Ebe Amr, Ali Amr, Bernd Lahrmann, Alan Lai, Christoph Reich, Chenyang Wang, Esther Herpel, Derliz Mereles, Lutz Frankenstein und 4 weitere

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.70019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Elham Kayvanpour und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, University of Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Cardiomyopathy, Dilated, Heart Ventricles, Myocardium. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The need to perform endomyocardial biopsy (EMB) in patients with non-ischaemic dilated cardiomyopathies (DCM) is debated. Here we sought to determine the extent of left ventricular collagen volume fraction (LV-CVF) in DCM patients and to evaluate it as a prognostic marker. Methods and results In this retrospective longitudinal study, we included 524 patients with suspected DCM who underwent left ventricular EMB (LV-EMB) as a part of their clinical work-up. LV-CVF was quantified using automated image processing of high-resolution scans of LV-EMB. Deep phenotyping was performed including assessment of late gadolinium enhancement on cardiac magnetic resonance imaging. Endpoints were (i) composite endpoint of heart failure-related death, sudden cardiac death, aborted sudden cardiac death (appropriate implantable cardioverter-defibrillator shock, reported sustained ventricular tachycardia, or cardiopulmonary resuscitation), or cardiac transplantation, and (ii) all-cause mortality. LV-EMB was associated with 0.76% major and 2.1% minor complications. No death occurred due to EMB. LV-CVF could be reliably quantified using Bayesian classification. During a median follow-up of 43.2 months (2084 patient-years), 48 patients with LV-CVF >32% and 14 patients with LV-CVF ≤32% reached the composite endpoint (log-rank p < 0.0001). A total of 62 patients reached the endpoint all-cause mortality, from which 38 presented with LV-CVF >32% and 17 with LV-CVF ≤32% (log-rank p = 0.009). In multivariable analyses, LV-CVF and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (hazard ratio 2.03, 95% confidence interval 1.32–3.11) were independent predictors of unfavourable outcome.

Conclusions

Left ventricular EMB is a safe diagnostic procedure. The extent of CVF in LV-EMB provides prognostic information in patients with DCM in addition to existing measures of left ventricular ejection fraction or NT-proBNP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, DilatedHeart VentriclesMyocardiumHumansFemaleMaleMiddle AgedRetrospective StudiesPrognosisBiopsyMagnetic Resonance Imaging, CineLongitudinal StudiesAgedDeath, Sudden, CardiacAdultCollagenFollow-Up Studies

Stichwörter der Autor:innen

Collagen volume fractionDilated cardiomyopathyLeft ventricular endomyocardial biopsyOutcome

Substanzen

Collagen

Autor:innen und Institutionen

  • Department of Medicine III, University of Heidelberg, Heidelberg, Germany.
  • DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany.
  • Hamamatsu Tissue Imaging and Analysis Center (BIOQUANT), Heidelberg, Germany.
  • Institute of Pathology, University Medical Center Göttingen UMG, Göttingen, Germany.
  • Roche Diagnostics GmbH, Mannheim, Germany.
  • Tissue Bank of the National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Zitieren

APA

Kayvanpour, E., Sedaghat-Hamedani, F., Li, D. T., Amr, E., Amr, A., Lahrmann, B., Lai, A., Reich, C., Wang, C., Herpel, E., Mereles, D., Frankenstein, L., Grabe, N., Katus, H. A., Frey, N., & Meder, B. (2025). Safety and Prognostic Value of Left Ventricular Endomyocardial Biopsy in Dilated Cardiomyopathy. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.70019

Vancouver

Kayvanpour E, Sedaghat-Hamedani F, Li DT, Amr E, Amr A, Lahrmann B, et al. Safety and Prognostic Value of Left Ventricular Endomyocardial Biopsy in Dilated Cardiomyopathy. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.70019

BibTeX
@article{Kayvanpour2025,
  author = {Kayvanpour, Elham and Sedaghat-Hamedani, Farbod and Li, Daniel Tian and Amr, Ebe and Amr, Ali and Lahrmann, Bernd and Lai, Alan and Reich, Christoph and Wang, Chenyang and Herpel, Esther and Mereles, Derliz and Frankenstein, Lutz and Grabe, Niels and Katus, Hugo A and Frey, Norbert and Meder, Benjamin},
  title = {Safety and Prognostic Value of Left Ventricular Endomyocardial Biopsy in Dilated Cardiomyopathy},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.70019}
}
Kostenlos starten →